{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T19:38:34Z","timestamp":1719603514846},"reference-count":83,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.029","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T04:24:44Z","timestamp":1527308684000},"page":"3650-3665","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4 + T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway"],"prefix":"10.1016","volume":"36","author":[{"given":"Sonia","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parakkal Jovvian","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Koussa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaela","family":"Parkhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott E.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lustigman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2018.05.029_b0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1473-3099(02)00366-3","article-title":"Influenza\u2013WHO cares","volume":"2","author":"Stohr","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.029_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1750-2659.2009.00073.x","article-title":"Estimates of US influenza-associated deaths made using four different methods","volume":"3","author":"Thompson","year":"2009","journal-title":"Influenza and Other Respirat Viruses"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.029_b0015","doi-asserted-by":"crossref","first-page":"e0118369","DOI":"10.1371\/journal.pone.0118369","article-title":"Estimating influenza disease burden from population-based surveillance data in the United States","volume":"10","author":"Reed","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2018.05.029_b0020","doi-asserted-by":"crossref","unstructured":"Foppa IM, Cheng PY, Reynolds SB, Shay DK, Carias C, Bresee JS, et al. Deaths averted by influenza vaccination in the U.S. during the seasons 2005\/06 through 2013\/1Vaccine. 2015;33(26):3003\u20139. http:\/\/doi.org\/10.1016\/j.vaccine.2015.02.042. (PubMed PMID: 25812842; PMCID: 4834450).","DOI":"10.1016\/j.vaccine.2015.02.042"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.029_b0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/infdis\/jis306","article-title":"Effectiveness of 1 dose of 2009 influenza A (H1N1) vaccine at preventing hospitalization with pandemic H1N1 influenza in children aged 7 months-9 years","volume":"206","author":"Hadler","year":"2012","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.029_b0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/infdis\/jiu185","article-title":"Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010\u20132012","volume":"210","author":"Ferdinands","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.029_b0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CIA.S25215","article-title":"Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence","volume":"7","author":"Lang","year":"2012","journal-title":"Clinical Intervent Aging"},{"issue":"16","key":"10.1016\/j.vaccine.2018.05.029_b0040","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.vaccine.2017.02.059","article-title":"Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: a systematic review and meta-analysis","volume":"35","author":"Lansbury","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.029_b0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","article-title":"Current and next generation influenza vaccines: Formulation and production strategies","volume":"94","author":"Soema","year":"2015","journal-title":"Eur J Pharm Biopharm: Official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV."},{"issue":"44","key":"10.1016\/j.vaccine.2018.05.029_b0050","first-page":"1241","article-title":"C, Prevention. Effectiveness of 2008\u201309 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) \u2013 United States, May-June 2009. MMWR","volume":"58","author":"Centers for Disease","year":"2009","journal-title":"Morbidi Mortality Weekly Report"},{"key":"10.1016\/j.vaccine.2018.05.029_b0055","doi-asserted-by":"crossref","unstructured":"Novel Swine-Origin Influenza AVIT, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New England J Med. 2009;360(25):2605\u201315. http:\/\/doi.org\/10.1056\/NEJMoa0903810. (PubMed PMID: 19423869).","DOI":"10.1056\/NEJMoa0903810"},{"key":"10.1016\/j.vaccine.2018.05.029_b0060","doi-asserted-by":"crossref","first-page":"b2425","DOI":"10.1136\/bmj.b2425","article-title":"World Health Organization declares A (H1N1) influenza pandemic","volume":"338","author":"Zarocostas","year":"2009","journal-title":"Bmj"},{"key":"10.1016\/j.vaccine.2018.05.029_b0065","doi-asserted-by":"crossref","first-page":"b3928","DOI":"10.1136\/bmj.b3928","article-title":"Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A\/H1N1 2009: case-control study in Mexico City","volume":"339","author":"Garcia-Garcia","year":"2009","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.029_b0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/14760584.2013.811193","article-title":"Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults","volume":"12","author":"McElhaney","year":"2013","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2018.05.029_b0075","first-page":"323","article-title":"Adjuvants for pandemic influenza vaccines","volume":"333","author":"Atmar","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.05.029_b0080","doi-asserted-by":"crossref","unstructured":"Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Trans Med. 2010;2(15):15ra5. http:\/\/doi.org\/10.1126\/scitranslmed.3000624. (PubMed PMID: 20371470).","DOI":"10.1126\/scitranslmed.3000624"},{"key":"10.1016\/j.vaccine.2018.05.029_b0085","doi-asserted-by":"crossref","unstructured":"Orsi A, Ansaldi F, de Florentiis D, Ceravolo A, Parodi V, Canepa P, et al. Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Human Vacc Immunotherap. 2013;9(3):582\u201390. (PubMed PMID: 23295230; PMCID: 3891715).","DOI":"10.4161\/hv.23239"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.029_b0090","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.vaccine.2016.01.003","article-title":"Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant, rOv-ASP-1","volume":"34","author":"Jiang","year":"2016","journal-title":"Vaccine"},{"issue":"9587","key":"10.1016\/j.vaccine.2018.05.029_b0095","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.029_b0100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.05.029_b0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fimmu.2013.00214","article-title":"Vaccine adjuvants: mode of action","volume":"4","author":"De Gregorio","year":"2013","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0110","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.05.029_b0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr Opin Immunol"},{"issue":"23","key":"10.1016\/j.vaccine.2018.05.029_b0120","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.vaccine.2014.03.046","article-title":"Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines","volume":"32","author":"Jiang","year":"2014","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2018.05.029_b0125","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1016\/j.vaccine.2005.01.098","article-title":"rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens","volume":"23","author":"MacDonald","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.029_b0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2249.2008.03623.x","article-title":"A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action","volume":"152","author":"MacDonald","year":"2008","journal-title":"Clin Experiment Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2018.05.029_b0135","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells","volume":"182","author":"He","year":"2009","journal-title":"J Immunol"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2018.05.029_b0140","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0264-410X(99)00371-0","article-title":"Hookworm burden reductions in BALB\/c mice vaccinated with recombinant Ancylostoma secreted proteins (ASPs) from Ancylostoma duodenale. Ancylostoma caninum and Necator americanus","volume":"18","author":"Sen","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.029_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2859-6-1","article-title":"Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis","volume":"6","author":"Cardoso","year":"2007","journal-title":"Microb Cell Fact"},{"issue":"17","key":"10.1016\/j.vaccine.2018.05.029_b0150","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1128\/JVI.00159-10","article-title":"Adaptation of pandemic H1N1 influenza viruses in mice","volume":"84","author":"Ilyushina","year":"2010","journal-title":"J Virol"},{"issue":"39","key":"10.1016\/j.vaccine.2018.05.029_b0155","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines","volume":"26","author":"Xiao","year":"2008","journal-title":"Vaccine"},{"issue":"5953","key":"10.1016\/j.vaccine.2018.05.029_b0160","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.1178258","article-title":"Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift","volume":"326","author":"Hensley","year":"2009","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.029_b0165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1586\/14760584.2016.1164046","article-title":"Influenza immunology evaluation and correlates of protection: a focus on vaccines","volume":"15","author":"Trombetta","year":"2016","journal-title":"Expert Rev Vacc"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.029_b0170","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2018.05.029_b0175","doi-asserted-by":"crossref","unstructured":"Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C et al. Inactivated H7 influenza virus vaccines protect mice despite inducing only low levels of neutralizing antibodies. J Virol 2017;91(20). http:\/\/doi.org\/10.1128\/JVI.01202-17. (PubMed PMID: 28768855; PMCID: PMC5625511).","DOI":"10.1128\/JVI.01202-17"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.029_b0180","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/CVI.00272-14","article-title":"An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans","volume":"21","author":"Krammer","year":"2014","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0185","doi-asserted-by":"crossref","first-page":"e1005578","DOI":"10.1371\/journal.ppat.1005578","article-title":"Broadly-reactive neutralizing and non-neutralizing antibodies directed against the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection","volume":"12","author":"Tan","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.05.029_b0190","doi-asserted-by":"crossref","unstructured":"Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, et al. Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge Model. mBio. 2017;8(5). http:\/\/doi.org\/10.1128\/mBio.01463-17. (PubMed PMID: 28928215; PMCID: PMC5605943).","DOI":"10.1128\/mBio.01463-17"},{"key":"10.1016\/j.vaccine.2018.05.029_b0195","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fimmu.2013.00421","article-title":"CD4(+) T cell priming as biomarker to study immune response to preventive vaccines","volume":"4","author":"Ciabattini","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.05.029_b0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2015.11.041","article-title":"Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity","volume":"3","author":"Martins","year":"2016","journal-title":"EBioMedicine"},{"issue":"15","key":"10.1016\/j.vaccine.2018.05.029_b0205","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1128\/JVI.00339-16","article-title":"Effects of MF59 Adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-Dependent influenza virus vaccine in the absence of CD4+ T cells","volume":"90","author":"Ko","year":"2016","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2018.05.029_b0210","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ni1275","article-title":"Immune cell migration in inflammation: present and future therapeutic targets","volume":"6","author":"Luster","year":"2005","journal-title":"Nature Immunol"},{"key":"10.1016\/j.vaccine.2018.05.029_b0215","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.vaccine.2018.05.029_b0220","doi-asserted-by":"crossref","unstructured":"Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511. Epub 2004\/07\/02. http:\/\/doi.org\/10.1038\/nri1391. (PubMed PMID: 15229469).","DOI":"10.1038\/nri1391"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.029_b0225","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.cr.7310019","article-title":"Antiviral innate immunity pathways","volume":"16","author":"Seth","year":"2006","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.029_b0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15585\/mmwr.mm6606a3","article-title":"Interim estimates of 2016\u201317 seasonal influenza vaccine effectiveness \u2013 United States, February 2017","volume":"66","author":"Flannery","year":"2017","journal-title":"MMWR Morb Mortality Week Rep"},{"key":"10.1016\/j.vaccine.2018.05.029_b0235","doi-asserted-by":"crossref","unstructured":"Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, et al. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PloS one. 2012;7(5):e37019. http:\/\/doi.org\/10.1371\/journal.pone.0037019. (PubMed PMID: 22615877; PMCID: 3355165).","DOI":"10.1371\/journal.pone.0037019"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.029_b0240","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/eji.200425719","article-title":"Decision criteria for resolving isotype switching conflicts by B cells","volume":"35","author":"Deenick","year":"2005","journal-title":"Eur J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.029_b0245","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1073\/pnas.082114899","article-title":"T-bet regulates IgG class switching and pathogenic autoantibody production","volume":"99","author":"Peng","year":"2002","journal-title":"Procee Nat Acad Sci United States of Am"},{"issue":"1\u20134","key":"10.1016\/j.vaccine.2018.05.029_b0250","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0165-2427(96)05684-X","article-title":"Differentiation of B cells in the bovine. Role of cytokines in immunoglobulin isotype expression","volume":"54","author":"Estes","year":"1996","journal-title":"Veterinary Immunol Immunopathol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.029_b0255","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","article-title":"CD4 T cells: fates, functions, and faults","volume":"112","author":"Zhu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.05.029_b0260","doi-asserted-by":"crossref","first-page":"925135","DOI":"10.1155\/2012\/925135","article-title":"CD4(+)T cells: differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin Develop Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2018.05.029_b0265","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1073\/pnas.0813390106","article-title":"Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels","volume":"106","author":"Galli","year":"2009","journal-title":"Procee Nat Acad Sci United States of Am"},{"issue":"23","key":"10.1016\/j.vaccine.2018.05.029_b0270","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1016\/j.vaccine.2007.03.045","article-title":"Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants","volume":"25","author":"Sokolovska","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2018.05.029_b0275","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2010.08.005","article-title":"Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide","volume":"31","author":"McAleer","year":"2010","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2018.05.029_b0280","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.20121517","article-title":"Revealing the role of CD4(+) T cells in viral immunity","volume":"209","author":"Sant","year":"2012","journal-title":"J Experiment Med"},{"key":"10.1016\/j.vaccine.2018.05.029_b0285","doi-asserted-by":"crossref","unstructured":"Ciurea A, Hunziker L, Klenerman P, Hengartner H, Zinkernagel RM. Impairment of CD4(+) T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J Experiment Med 2001;193(3):297-305. (PubMed PMID: 11157050; PMCID: 2195917).","DOI":"10.1084\/jem.193.3.297"},{"issue":"2","key":"10.1016\/j.vaccine.2018.05.029_b0290","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/infdis\/jis684","article-title":"CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine","volume":"207","author":"Nayak","year":"2013","journal-title":"J Infect Dis"},{"issue":"24","key":"10.1016\/j.vaccine.2018.05.029_b0295","doi-asserted-by":"crossref","first-page":"13310","DOI":"10.1128\/JVI.05728-11","article-title":"Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus","volume":"85","author":"Alam","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.05.029_b0300","first-page":"w13940","article-title":"Vaccine adjuvants\u2013understanding molecular mechanisms to improve vaccines","volume":"144","author":"Egli","year":"2014","journal-title":"Swiss Med Week"},{"issue":"13","key":"10.1016\/j.vaccine.2018.05.029_b0305","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.029_b0310","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.tips.2009.03.005","article-title":"Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants","volume":"30","author":"Aimanianda","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"29","key":"10.1016\/j.vaccine.2018.05.029_b0315","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 \u2013 an innately attractive adjuvant formulation","volume":"30","author":"O'Hagan","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0320","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev Vacc"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0325","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1038\/cti.2016.19","article-title":"Local innate immune responses in the vaccine adjuvant-injected muscle","volume":"5","author":"Liang","year":"2016","journal-title":"Clin Trans Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2018.05.029_b0330","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.vaccine.2017.02.005","article-title":"Dynamics of APC recruitment at the site of injection following injection of vaccine adjuvants","volume":"35","author":"van Aalst","year":"2017","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2018.05.029_b0335","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.029_b0340","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4049\/jimmunol.163.5.2829","article-title":"Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists","volume":"163","author":"McColl","year":"1999","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0345","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1615\/CritRevImmunol.v26.i4.20","article-title":"Neutrophil infiltration and chemokines","volume":"26","author":"Kobayashi","year":"2006","journal-title":"Critic Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.029_b0350","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/08977190500055836","article-title":"G-CSF: a key regulator of neutrophil production, but that's not all!","volume":"23","author":"Roberts","year":"2005","journal-title":"Growth Factors"},{"issue":"3","key":"10.1016\/j.vaccine.2018.05.029_b0355","first-page":"121","article-title":"CXCL10\/IP-10 in infectious diseases pathogenesis and potential therapeutic implications","volume":"22","author":"Liu","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.029_b0360","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res: Official J Int Soc Interferon Cytokine Res"},{"key":"10.1016\/j.vaccine.2018.05.029_b0365","doi-asserted-by":"crossref","unstructured":"Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. Identification and characterization of macrophage inflammatory protein 2. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(2):612\u20136. (PubMed PMID: 2643119; PMCID: 286522).","DOI":"10.1073\/pnas.86.2.612"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.029_b0370","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nature Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0375","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1568008043339712","article-title":"Chemokine-chemokine receptor network in immune cell trafficking","volume":"4","author":"Kim","year":"2004","journal-title":"Current Drug Targets Immune, Endocrine Metabolic Disorders"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.029_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2050-7771-2-1","article-title":"Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases","volume":"2","author":"Yang","year":"2014","journal-title":"Biomarker Res"},{"key":"10.1016\/j.vaccine.2018.05.029_b0385","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12929-014-0099-6","article-title":"The pathological effects of CCR2+ inflammatory monocytes are amplified by an IFNAR1-triggered chemokine feedback loop in highly pathogenic influenza infection","volume":"21","author":"Lin","year":"2014","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2018.05.029_b0390","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.1005201108","article-title":"Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue","volume":"108","author":"Iijima","year":"2011","journal-title":"Procee Nat Acad Sci United States of Am"},{"issue":"4","key":"10.1016\/j.vaccine.2018.05.029_b0395","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.smim.2009.05.005","article-title":"Modulation of adaptive immunity with Toll-like receptors","volume":"21","author":"Manicassamy","year":"2009","journal-title":"Semin Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2018.05.029_b0400","doi-asserted-by":"crossref","first-page":"12713","DOI":"10.1128\/JVI.01675-10","article-title":"MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection","volume":"84","author":"Seo","year":"2010","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.05.029_b0405","doi-asserted-by":"crossref","first-page":"e5674","DOI":"10.1371\/journal.pone.0005674","article-title":"TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA","volume":"4","author":"Konno","year":"2009","journal-title":"PLoS One"},{"issue":"52","key":"10.1016\/j.vaccine.2018.05.029_b0410","doi-asserted-by":"crossref","first-page":"36211","DOI":"10.1074\/jbc.M806576200","article-title":"TRAF6 and MEKK1 play a pivotal role in the RIG-I-like helicase antiviral pathway","volume":"283","author":"Yoshida","year":"2008","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.vaccine.2018.05.029_b0415","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr Opin Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:47:39Z","timestamp":1693687659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":83,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306364"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}